|
9 Companies |
|
9 Products |
|
9 Products |
|
11 Mechanisms of Action |
|
0 Trials |
|
35 News |
|
- | Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
Trial withdrawal: A1AT for NMO: Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses (clinicaltrials.gov) - Apr 19, 2019
P1, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Withdrawn
- | autologous mesenchymal stem cells / Tianjin Medical University General Hospital
Trial completion, Phase classification: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) - Oct 17, 2018
P2a, N=15, Completed, Sponsor: Tianjin Medical University General Hospital
Recruiting --> Withdrawn Recruiting --> Completed | Phase classification: P2 --> P2a
- | dalfampridine / Generic mfg.
Trial completion, Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Jan 9, 2018
P2, N=24, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed | Phase classification: P2 --> P2a Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017
- | aHSCT / University of Calgary
Trial termination: SCT-NMO: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=3, Terminated, Sponsor: University of Calgary
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017 Active, not recruiting --> Terminated; recruitment failure
- | Trial completion: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Oct 17, 2017
P=N/A, N=178, Completed, Sponsor: University of Michigan
Active, not recruiting --> Terminated; recruitment failure Active, not recruiting --> Completed
- dalfampridine / Generic mfg.
Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Aug 18, 2017
P2, N=25, Active, not recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Trial primary completion date: Nov 2016 --> May 2017
- | Enrollment closed, Phase classification, Trial primary completion date: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - May 17, 2017
P=N/A, N=178, Active, not recruiting, Sponsor: University of Michigan
Trial primary completion date: Nov 2016 --> May 2017 Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A | Trial primary completion date: Sep 2018 --> Sep 2017
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Apr 12, 2017
P2, N=7, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A | Trial primary completion date: Sep 2018 --> Sep 2017 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015
- dalfampridine / Generic mfg.
Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Dec 21, 2016
P2, N=25, Active, not recruiting, Sponsor: Johns Hopkins University
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015 Trial primary completion date: Jan 2016 --> Nov 2016
- Trial primary completion date: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Oct 25, 2016
P3, N=200, Recruiting, Sponsor: University of Michigan
Trial primary completion date: Jan 2016 --> Nov 2016 Trial primary completion date: Apr 2016 --> Sep 2018
- Trial primary completion date: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Jan 17, 2016
P3, N=200, Recruiting, Sponsor: University of Michigan
Trial primary completion date: Apr 2016 --> Sep 2018 Trial primary completion date: Dec 2015 --> Apr 2016
- aHSCT / University of Calgary
Enrollment closed, Enrollment change: SCT-NMO: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (clinicaltrials.gov) - Jan 4, 2016
P1/2, N=3, Active, not recruiting, Sponsor: University of Calgary
Trial primary completion date: Dec 2015 --> Apr 2016 Recruiting --> Active, not recruiting | N=10 --> 3
- | dalfampridine / Generic mfg.
Enrollment closed: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Oct 2, 2015
P2, N=25, Active, not recruiting, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting | N=10 --> 3 Recruiting --> Active, not recruiting
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Jun 12, 2015
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Dec 2015
- Avastin (bevacizumab) / Roche
Trial completion: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - May 29, 2015
P1, N=10, Completed, Sponsor: Johns Hopkins University
Trial primary completion date: Mar 2015 --> Dec 2015 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Mar 12, 2015
P1, N=10, Active, not recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> May 2015
- || New P3 trial: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Jan 20, 2015
P3, N=200, Recruiting, Sponsor: University of Michigan
- aHSCT / University of Calgary
Trial primary completion date: SCT-NMO: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=10, Recruiting, Sponsor: University of Calgary
Trial primary completion date: Jan 2015 --> May 2015 Trial primary completion date: Mar 2017 --> Mar 2020
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Oct 17, 2014
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Trial primary completion date: Mar 2017 --> Mar 2020 Trial primary completion date: Mar 2014 --> Mar 2015
- Avastin (bevacizumab) / Roche
Enrollment closed: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Sep 30, 2014
P1, N=10, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- autologous mesenchymal stem cells / Tianjin Medical University General Hospital
New P2 trial: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) - Sep 28, 2014
P2, N=15, Recruiting, Sponsor: Tianjin Medical University General Hospital
- | dalfampridine / Generic mfg.
New P2 trial: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Jun 19, 2014
P2, N=25, Recruiting, Sponsor: Johns Hopkins University
- Avastin (bevacizumab) / Roche
Phase classification: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Jun 12, 2014
P1, N=10, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting Phase classification: P2 --> P1
- Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
Clinical: A1AT for NMO: Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses (clinicaltrials.gov) - Mar 12, 2014
P1, N=5, Recruiting, Sponsor: Stanford University
- Avastin (bevacizumab) / Roche
Enrollment open: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Jan 21, 2014
P2, N=10, Recruiting, Sponsor: Johns Hopkins University
Phase classification: P2 --> P1 Not yet recruiting --> Recruiting
- dalfampridine / Generic mfg.
Trial termination: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (clinicaltrials.gov) - Jan 13, 2014
P4, N=8, Terminated, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting Recruiting --> Terminated; This study was redesigned to be more statistically rigorous.
- dalfampridine / Generic mfg.
Enrollment change: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (clinicaltrials.gov) - Jan 13, 2014
P4, N=8, Terminated, Sponsor: Johns Hopkins University
Recruiting --> Terminated; This study was redesigned to be more statistically rigorous. N=50 --> 8
- Cinryze IV (C1 esterase inhibitor [human] IV) / Takeda
Trial completion: C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation (clinicaltrials.gov) - Nov 17, 2013
P1, N=10, Completed, Sponsor: Michael Levy
N=50 --> 8 Recruiting --> Completed
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Jul 9, 2013
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Completed Not yet recruiting --> Recruiting
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P2 trial: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - May 1, 2013
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- Avastin (bevacizumab) / Roche
New P2 trial: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Jan 24, 2013
P2, N=10, Recruiting, Sponsor: Johns Hopkins University
- Cinryze IV (C1 esterase inhibitor [human] IV) / Takeda
New P1 trial: C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation (clinicaltrials.gov) - Jan 1, 2013
P1, N=10, Completed, Sponsor: Michael Levy
- dalfampridine / Generic mfg.
Trial initiation date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (clinicaltrials.gov) - Mar 27, 2012
P4, N=8, Terminated, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting Initiation date: Jan 2012 --> Jul 2012
- dalfampridine / Generic mfg.
New P4 trial: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (clinicaltrials.gov) - Oct 3, 2011
P4, N=8, Terminated, Sponsor: Johns Hopkins University
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Safety and Tolerability of Rituximab in Neuromyelitis Optica (clinicaltrials.gov) - Sep 25, 2011
P1, N=20, Completed, Sponsor: University of California, San Francisco
Initiation date: Jan 2012 --> Jul 2012 Active, not recruiting --> Completed